Biological
Autologous Tumor Infiltrating Lymphocytes LN-145 clinical trials
Also written LN-145.
- studies test it
- 14
- open now
- 6
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the Autologous Tumor Infiltrating Lymphocytes LN-145 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2017 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 6
Iovance Biotherapeutics, Inc. (6) · Vastra Gotaland Region (2) · Shanghai Juncell Therapeutics (2) · Karam Khaddour, MD, MS (1) · Zhiyong Huang (1) · Gregory Daniels (1) · Roswell Park Cancer Institute (1)
Often tested with
Tested in the same studies.
Lifileucel (13) · Autologous Tumor Infiltrating Lymphocytes LN-145-S1 (2) · Interleukin-2 (2) · Pembrolizumab (2) · Melphalan (1) · Cyclophosphamide (1) · Fludarabine (1) · Durvalumab (1)
Studies
Open first, then newest update. How each study uses Autologous Tumor Infiltrating Lymphocytes LN-145 is read from its arms, and is right about nine times in ten.
Testing it · 14
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingPhase 1Vastra Gotaland RegionNCT05903937Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase Ib Study of GC101 in NSCLCRecruitingPhase 1Shanghai Juncell TherapeuticsNCT06473961Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase II Study of GC101 in NSCLCRecruitingPhase 2Shanghai Juncell TherapeuticsNCT07560111Written as Autologous Tumor Infiltrating Lymphocytes
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerRecruitingPhase 2Iovance Biotherapeutics, Inc.NCT04614103Written as LN-145
- TIL Therapy in cSCC and MCCRecruitingPhase 2Karam Khaddour, MD, MSNCT07288073Written as LN-145
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver CancerRecruitingPhase 1Zhiyong HuangNCT06084299Written as Autologous Tumor Infiltrating Lymphocytes
- Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsTerminatedPhase 1Iovance Biotherapeutics, Inc.NCT06566092Written as LN-145/LN-144
- Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03108495Written as LN-145
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03645928Written as LN-145
- Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver MetastasesCompletedPhase 1Vastra Gotaland RegionNCT04812470Written as Autologous Tumor Infiltrating Lymphocytes
- Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid TumorsTerminatedPhase 1Gregory DanielsNCT03991741Written as Autologous Tumor Infiltrating Lymphocytes
- Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckCompletedPhase 2Iovance Biotherapeutics, Inc.NCT03083873Written as LN-145
- Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyWithdrawnPhase 2Roswell Park Cancer InstituteNCT03935347Written as Autologous Tumor Infiltrating Lymphocytes LN-145
- Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerWithdrawnPhase 2Iovance Biotherapeutics, Inc.NCT03419559Written as LN-145